Yes
|
o |
No
x
|
Yes
|
o |
No
x
|
Yes
|
o |
No
x
|
This
Report of Foreign Issuer on Form 6-K is incorporated by reference into the
Post-Effective Amendments on Forms F-3 and S-8
to the
Registration Statement on Form F-3 of Elan Corporation, plc (Registration
No. 333-100252), and
the Registration Statements on Form S-8 of Elan Corporation, plc
(Registration Nos. 333-100556,
333-07361, 333-121021, 333-135184, 333-135185 and
333-154573).
|
Exhibit
|
Description
|
99.1
|
Press
release dated July 13, 2009 titled:
Elan
and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves
Desired Concentrations in Brain Tissue and Cerebrospinal
Fluid.
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
||
ELAN
CORPORATION, plc
By: /s/ William F.
Daniel
William F. Daniel
EVP, Company Secretary
|